Anti-nociceptive	B:C0243095
roles	I:C0243095
of	O
the	O
glia	O
-	O
specific	O
metabolic	O
inhibitor	I:C0021469
fluorocitrate	O
in	O
paclitaxel	O
-	O
evoked	O
neuropathic	O
pain	I:C3714625
.	O

Anti-nociceptive	O
roles	I:C0243095
of	O
the	O
glia	B:C0027836
-	O
specific	O
metabolic	O
inhibitor	I:C0021469
fluorocitrate	O
in	O
paclitaxel	O
-	O
evoked	O
neuropathic	O
pain	I:C3714625
.	O

Anti-nociceptive	O
roles	I:C0243095
of	O
the	O
glia	O
-	O
specific	O
metabolic	B:C0021469
inhibitor	I:C0021469
fluorocitrate	O
in	O
paclitaxel	O
-	O
evoked	O
neuropathic	O
pain	I:C3714625
.	O

Anti-nociceptive	O
roles	I:C0243095
of	O
the	O
glia	O
-	O
specific	O
metabolic	O
inhibitor	I:C0021469
fluorocitrate	B:C0060559
in	O
paclitaxel	O
-	O
evoked	O
neuropathic	O
pain	I:C3714625
.	O

Anti-nociceptive	O
roles	I:C0243095
of	O
the	O
glia	O
-	O
specific	O
metabolic	O
inhibitor	I:C0021469
fluorocitrate	O
in	O
paclitaxel	B:C0144576
-	O
evoked	O
neuropathic	O
pain	I:C3714625
.	O

Anti-nociceptive	O
roles	I:C0243095
of	O
the	O
glia	O
-	O
specific	O
metabolic	O
inhibitor	I:C0021469
fluorocitrate	O
in	O
paclitaxel	O
-	O
evoked	O
neuropathic	B:C3714625
pain	I:C3714625
.	O

Paclitaxel	B:C0144576
(	O
Taxol	O
)	O
is	O
a	O
powerful	O
chemotherapy	O
drug	O
used	O
in	O
breast	O
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	O
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	O
and	O
poor	O
treatment	O
outcomes	O
.	O

Paclitaxel	O
(	O
Taxol	B:C0678133
)	O
is	O
a	O
powerful	O
chemotherapy	O
drug	O
used	O
in	O
breast	O
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	O
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	O
and	O
poor	O
treatment	O
outcomes	O
.	O

Paclitaxel	O
(	O
Taxol	O
)	O
is	O
a	O
powerful	O
chemotherapy	B:C3665472
drug	O
used	O
in	O
breast	O
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	O
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	O
and	O
poor	O
treatment	O
outcomes	O
.	O

Paclitaxel	O
(	O
Taxol	O
)	O
is	O
a	O
powerful	O
chemotherapy	O
drug	B:C1254351
used	O
in	O
breast	O
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	O
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	O
and	O
poor	O
treatment	O
outcomes	O
.	O

Paclitaxel	O
(	O
Taxol	O
)	O
is	O
a	O
powerful	O
chemotherapy	O
drug	O
used	O
in	O
breast	B:C0678222
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	O
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	O
and	O
poor	O
treatment	O
outcomes	O
.	O

Paclitaxel	O
(	O
Taxol	O
)	O
is	O
a	O
powerful	O
chemotherapy	O
drug	O
used	O
in	O
breast	O
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	B:C3714625
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	O
and	O
poor	O
treatment	O
outcomes	O
.	O

Paclitaxel	O
(	O
Taxol	O
)	O
is	O
a	O
powerful	O
chemotherapy	O
drug	O
used	O
in	O
breast	O
cancers	I:C0678222
,	O
but	O
it	O
often	O
causes	O
neuropathic	O
pain	I:C3714625
,	O
leading	O
to	O
the	O
early	O
cessation	O
of	O
therapy	B:C0087111
and	O
poor	O
treatment	O
outcomes	O
.	O

Approaches	O
for	O
the	O
management	B:C0376636
of	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
are	O
urgently	O
needed	O
.	O

Approaches	O
for	O
the	O
management	O
of	O
paclitaxel	B:C0144576
-	O
induced	O
neuropathic	O
pain	I:C3714625
are	O
urgently	O
needed	O
.	O

Approaches	O
for	O
the	O
management	O
of	O
paclitaxel	O
-	O
induced	O
neuropathic	B:C3714625
pain	I:C3714625
are	O
urgently	O
needed	O
.	O

The	O
involvement	O
of	O
spinal	B:C0037925
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	B:C0004112
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	B:C0699748
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	B:C0144576
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	B:C0442874
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	B:C0060559
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	B:C0060559
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	B:C1326121
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	B:C3714625
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	B:C0144576
treatment	O
.	O

The	O
involvement	O
of	O
spinal	O
astrocytes	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	O
-	O
induced	O
neuropathy	O
has	O
been	O
reported	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
fluorocitrate	O
(	O
fluorocitrate	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
astrocyte	O
activation	I:C1326121
,	O
during	O
neuropathic	O
pain	I:C3714625
related	O
to	O
paclitaxel	O
treatment	B:C0087111
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
investigated	O
the	O
effects	O
of	O
fluorocitrate	O
on	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
fluorocitrate	B:C0060559
on	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
fluorocitrate	O
on	O
paclitaxel	B:C0144576
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
fluorocitrate	O
on	O
paclitaxel	O
-	O
induced	O
neuropathic	B:C3714625
pain	I:C3714625
.	O

Glial	B:C0017626
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
(	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
)	O
expression	O
was	O
determined	O
to	O
assess	O
astrocyte	O
activation	I:C1326121
.	O

Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
(	O
Glial	B:C0017626
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
)	O
expression	O
was	O
determined	O
to	O
assess	O
astrocyte	O
activation	I:C1326121
.	O

Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
(	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
)	O
expression	B:C1171362
was	O
determined	O
to	O
assess	O
astrocyte	O
activation	I:C1326121
.	O

Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
(	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
)	O
expression	O
was	O
determined	O
to	O
assess	O
astrocyte	B:C1326121
activation	I:C1326121
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	B:C1171362
of	O
glial	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	O
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	O
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	O
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	O
of	O
glial	B:C0027836
glutamate	O
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	O
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	O
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	O
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	O
of	O
glial	O
glutamate	B:C0061467
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	O
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	O
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	O
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	O
of	O
glial	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	B:C0061467
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	O
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	O
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	O
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	O
of	O
glial	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	B:C0752312
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	O
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	O
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	O
of	O
glial	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	O
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	B:C0228564
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	O
.	O

To	O
explore	O
the	O
mechanisms	O
involved	O
,	O
the	O
expression	O
of	O
glial	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
(	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
)	O
and	O
the	O
activation	O
of	O
mitogen	O
-	I:C0752312
activated	I:C0752312
protein	I:C0752312
kinases	I:C0752312
in	O
the	O
spinal	O
dorsal	I:C0228564
horn	I:C0228564
were	O
analyzed	B:C0936012
.	O

The	O
results	O
showed	O
that	O
paclitaxel	B:C0144576
decreased	O
the	O
mechanical	O
nociceptive	I:C3893396
thresholds	O
and	O
increased	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
expression	O
,	O
leading	O
to	O
spinal	O
astrocyte	O
activation	I:C1326121
.	O

The	O
results	O
showed	O
that	O
paclitaxel	O
decreased	O
the	O
mechanical	B:C3893396
nociceptive	I:C3893396
thresholds	O
and	O
increased	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
expression	O
,	O
leading	O
to	O
spinal	O
astrocyte	O
activation	I:C1326121
.	O

The	O
results	O
showed	O
that	O
paclitaxel	O
decreased	O
the	O
mechanical	O
nociceptive	I:C3893396
thresholds	O
and	O
increased	O
Glial	B:C0017626
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
expression	O
,	O
leading	O
to	O
spinal	O
astrocyte	O
activation	I:C1326121
.	O

The	O
results	O
showed	O
that	O
paclitaxel	O
decreased	O
the	O
mechanical	O
nociceptive	I:C3893396
thresholds	O
and	O
increased	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
expression	B:C1171362
,	O
leading	O
to	O
spinal	O
astrocyte	O
activation	I:C1326121
.	O

The	O
results	O
showed	O
that	O
paclitaxel	O
decreased	O
the	O
mechanical	O
nociceptive	I:C3893396
thresholds	O
and	O
increased	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
expression	O
,	O
leading	O
to	O
spinal	B:C0037925
astrocyte	O
activation	I:C1326121
.	O

The	O
results	O
showed	O
that	O
paclitaxel	O
decreased	O
the	O
mechanical	O
nociceptive	I:C3893396
thresholds	O
and	O
increased	O
Glial	O
fibrillary	I:C0017626
acidic	I:C0017626
protein	I:C0017626
expression	O
,	O
leading	O
to	O
spinal	O
astrocyte	B:C1326121
activation	I:C1326121
.	O

After	O
paclitaxel	B:C0144576
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	B:C0087111
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	B:C0061467
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	B:C0013081
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	B:C0031715
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	B:C0082529
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	B:C0170168
and	O
JNK	O
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	B:C0248813
were	O
obviously	O
up	O
-	I:C0041904
regulated	I:C0041904
.	O

After	O
paclitaxel	O
treatment	O
,	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
was	O
significantly	O
down	O
-	I:C0013081
regulated	I:C0013081
,	O
and	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
were	O
obviously	O
up	B:C0041904
-	I:C0041904
regulated	I:C0041904
.	O

However	O
,	O
paclitaxel	B:C0144576
treatment	O
did	O
not	O
increase	O
p38	O
phosphorylation	O
.	O

However	O
,	O
paclitaxel	O
treatment	B:C0087111
did	O
not	O
increase	O
p38	O
phosphorylation	O
.	O

However	O
,	O
paclitaxel	O
treatment	O
did	O
not	O
increase	O
p38	B:C1120843
phosphorylation	O
.	O

However	O
,	O
paclitaxel	O
treatment	O
did	O
not	O
increase	O
p38	O
phosphorylation	B:C0031715
.	O

Additional	O
studies	B:C2603343
showed	O
that	O
paclitaxel	O
-	O
evoked	O
mechanical	O
hypersensitivity	O
was	O
reduced	O
by	O
fluorocitrate	O
treatment	O
.	O

Additional	O
studies	O
showed	O
that	O
paclitaxel	B:C0144576
-	O
evoked	O
mechanical	O
hypersensitivity	O
was	O
reduced	O
by	O
fluorocitrate	O
treatment	O
.	O

Additional	O
studies	O
showed	O
that	O
paclitaxel	O
-	O
evoked	O
mechanical	O
hypersensitivity	B:C0020517
was	O
reduced	O
by	O
fluorocitrate	O
treatment	O
.	O

Additional	O
studies	O
showed	O
that	O
paclitaxel	O
-	O
evoked	O
mechanical	O
hypersensitivity	O
was	O
reduced	O
by	O
fluorocitrate	B:C0060559
treatment	O
.	O

Additional	O
studies	O
showed	O
that	O
paclitaxel	O
-	O
evoked	O
mechanical	O
hypersensitivity	O
was	O
reduced	O
by	O
fluorocitrate	O
treatment	B:C0087111
.	O

Moreover	O
,	O
fluorocitrate	B:C0060559
treatment	O
inhibited	O
the	O
activation	O
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
expression	O
and	O
MAPK	O
phosphorylation	O
.	O

Moreover	O
,	O
fluorocitrate	O
treatment	B:C0087111
inhibited	O
the	O
activation	O
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
expression	O
and	O
MAPK	O
phosphorylation	O
.	O

Moreover	O
,	O
fluorocitrate	O
treatment	O
inhibited	O
the	O
activation	B:C1326121
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
expression	O
and	O
MAPK	O
phosphorylation	O
.	O

Moreover	O
,	O
fluorocitrate	O
treatment	O
inhibited	O
the	O
activation	O
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	B:C0061467
transporter	I:C0061467
1	I:C0061467
expression	O
and	O
MAPK	O
phosphorylation	O
.	O

Moreover	O
,	O
fluorocitrate	O
treatment	O
inhibited	O
the	O
activation	O
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
expression	B:C1171362
and	O
MAPK	O
phosphorylation	O
.	O

Moreover	O
,	O
fluorocitrate	O
treatment	O
inhibited	O
the	O
activation	O
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
expression	O
and	O
MAPK	B:C0752312
phosphorylation	O
.	O

Moreover	O
,	O
fluorocitrate	O
treatment	O
inhibited	O
the	O
activation	O
of	I:C1326121
astrocytes	I:C1326121
and	O
reversed	O
the	O
changes	O
in	O
glutamate	O
transporter	I:C0061467
1	I:C0061467
expression	O
and	O
MAPK	O
phosphorylation	B:C0031715
.	O

Further	O
study	B:C2603343
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	B:C0060559
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	B:C0243095
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	B:C0144576
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	B:C0060559
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	B:C0144576
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	B:C3714625
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	O
effect	I:C0243095
.	O

Further	O
study	O
indicated	O
that	O
fluorocitrate	O
did	O
not	O
influence	O
the	O
antitumor	O
effect	I:C0243095
of	O
paclitaxel	O
,	O
suggesting	O
that	O
fluorocitrate	O
blocked	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
without	O
antagonizing	O
its	O
antitumor	B:C0243095
effect	I:C0243095
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	B:C0144576
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	B:C1326121
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	B:C2936719
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	B:C0020429
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	B:C0060559
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	B:C1611640
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	B:C0144576
-	O
induced	O
neuropathic	O
pain	I:C3714625
.	O

Together	O
,	O
these	O
results	O
suggested	O
that	O
paclitaxel	O
induced	O
astrocyte	O
-	I:C1326121
specific	I:C1326121
activation	I:C1326121
,	O
which	O
may	O
contribute	O
to	O
mechanical	O
allodynia	I:C2936719
and	O
hyperalgesia	O
,	O
and	O
that	O
fluorocitrate	O
could	O
be	O
a	O
potential	O
therapeutic	O
agent	I:C1611640
for	O
paclitaxel	O
-	O
induced	O
neuropathic	B:C3714625
pain	I:C3714625
.	O

